Other News To Note
Wednesday, November 14, 2012
CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7.1 showed promising safety and tolerability in heavily pretreated solid tumors. The compound also demonstrated signs of efficacy in most treated patients, suggesting longer overall survival in lung, hypopharnyx, ovarian, testicular, stomach, esophageal, biliary tract and neuroendocrine tumors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.